Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS anti-PD-1 — Clinical regulatory milestone payments

Similar metrics at other companies

AnaptysBio, Inc. logo
ANABAnaptys Bio Generated Anti PD1Jemperli Dostarlimab — Revenue Recognition Milestone Method Contingent
$15M-89.3%
Tarsus Pharmaceuticals, Inc. logo
TARSDevelopment and Regulatory Milestone — Milestone payments to be achieved
$67.5M0.0%
Relmada Therapeutics, Inc. logo
RLMDMilestone Payments
$500K—
Dianthus Therapeutics logo
DNTHFirst Selected Antibody — Potential Milestone Payments Due
$11M0.0%
Denali Therapeutics Inc. logo
DNLIPeripheral Program License — Milestone payments upon achievement of certain clinical, regulatory and sales milestone events
$495M—
Insmed logo
INSMPayment Of Milestone
$15M—

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.8B+317%
Enterprise value$3.72B+376%
P/S16.1×+9.6×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept rcus:ClinicalRegulatoryMilestonePayments.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's anti-pd-1 — clinical regulatory milestone payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's anti-pd-1 — clinical regulatory milestone payments?
Arcus Biosciences (RCUS) reported anti-pd-1 — clinical regulatory milestone payments of $50M in Q1 2026.
How has Arcus Biosciences's anti-pd-1 — clinical regulatory milestone payments changed year-over-year?
Arcus Biosciences's anti-pd-1 — clinical regulatory milestone payments decreased by 0.0% year-over-year, from $50M to $50M.
What does anti-pd-1 — clinical regulatory milestone payments mean?
Represents payments triggered by the achievement of specific clinical trial outcomes or regulatory approvals for anti-PD-1 therapeutic candidates. These costs reflect the successful progression of a drug candidate through the development pipeline toward potential market authorization. Investors monitor these to gauge the technical and regulatory advancement of the company's immuno-oncology portfolio.